The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Late Stage Chronic Kidney Disease Drugs Market Research Report 2025

Global Late Stage Chronic Kidney Disease Drugs Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1935669

No of Pages : 86

Ask Your Query

Synopsis

Late stage chronic kidney disease therapeutics can be defined as the drugs which are used for the treatment of late-stage CKD - Induced, Hyperphosphatemia, Hyperparathyroidism and Hyperkalemia.

The global Late Stage Chronic Kidney Disease Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs.

However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Late Stage Chronic Kidney Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Late Stage Chronic Kidney Disease Drugs.

Report Scope

The Late Stage Chronic Kidney Disease Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Late Stage Chronic Kidney Disease Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Late Stage Chronic Kidney Disease Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • AbbVie
  • Amgen
  • Ardelyx
  • AstraZeneca
  • Deltanoid
  • Akebia Therapeutics
  • Kyowa Hakko Kirin
  • OPKO Health
  • Vifor Pharma
  • Sanofi
  • Shield Therapeutics
  • Shire
  • Spectrum
  • ZS Pharma

Segment by Type

  • Calcimimetics
  • Vitamin D Sterols
  • Potassium Binders
  • Others

Segment by Application

  • Hospital Pharmacies
  • Online Pharnacies
  • Retail Pharmacies

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Netherlands)
  • Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
  • Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Late Stage Chronic Kidney Disease Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Calcimimetics
1.2.3 Vitamin D Sterols
1.2.4 Potassium Binders
1.2.5 Others
1.3 Market by Application
1.3.1 Global Late Stage Chronic Kidney Disease Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Online Pharnacies
1.3.4 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Late Stage Chronic Kidney Disease Drugs Market Perspective (2019-2030)
2.2 Late Stage Chronic Kidney Disease Drugs Growth Trends by Region
2.2.1 Global Late Stage Chronic Kidney Disease Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Late Stage Chronic Kidney Disease Drugs Historic Market Size by Region (2019-2024)
2.2.3 Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Region (2025-2030)
2.3 Late Stage Chronic Kidney Disease Drugs Market Dynamics
2.3.1 Late Stage Chronic Kidney Disease Drugs Industry Trends
2.3.2 Late Stage Chronic Kidney Disease Drugs Market Drivers
2.3.3 Late Stage Chronic Kidney Disease Drugs Market Challenges
2.3.4 Late Stage Chronic Kidney Disease Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Late Stage Chronic Kidney Disease Drugs Players by Revenue
3.1.1 Global Top Late Stage Chronic Kidney Disease Drugs Players by Revenue (2019-2024)
3.1.2 Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Late Stage Chronic Kidney Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Late Stage Chronic Kidney Disease Drugs Revenue
3.4 Global Late Stage Chronic Kidney Disease Drugs Market Concentration Ratio
3.4.1 Global Late Stage Chronic Kidney Disease Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Late Stage Chronic Kidney Disease Drugs Revenue in 2023
3.5 Late Stage Chronic Kidney Disease Drugs Key Players Head office and Area Served
3.6 Key Players Late Stage Chronic Kidney Disease Drugs Product Solution and Service
3.7 Date of Enter into Late Stage Chronic Kidney Disease Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Late Stage Chronic Kidney Disease Drugs Breakdown Data by Type
4.1 Global Late Stage Chronic Kidney Disease Drugs Historic Market Size by Type (2019-2024)
4.2 Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Type (2025-2030)
5 Late Stage Chronic Kidney Disease Drugs Breakdown Data by Application
5.1 Global Late Stage Chronic Kidney Disease Drugs Historic Market Size by Application (2019-2024)
5.2 Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Late Stage Chronic Kidney Disease Drugs Market Size (2019-2030)
6.2 North America Late Stage Chronic Kidney Disease Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2019-2024)
6.4 North America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Late Stage Chronic Kidney Disease Drugs Market Size (2019-2030)
7.2 Europe Late Stage Chronic Kidney Disease Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2019-2024)
7.4 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size (2019-2030)
8.2 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Late Stage Chronic Kidney Disease Drugs Market Size (2019-2030)
9.2 Latin America Late Stage Chronic Kidney Disease Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2019-2024)
9.4 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size (2019-2030)
10.2 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Late Stage Chronic Kidney Disease Drugs Introduction
11.1.4 AbbVie Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Late Stage Chronic Kidney Disease Drugs Introduction
11.2.4 Amgen Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 Ardelyx
11.3.1 Ardelyx Company Detail
11.3.2 Ardelyx Business Overview
11.3.3 Ardelyx Late Stage Chronic Kidney Disease Drugs Introduction
11.3.4 Ardelyx Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.3.5 Ardelyx Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Late Stage Chronic Kidney Disease Drugs Introduction
11.4.4 AstraZeneca Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.4.5 AstraZeneca Recent Development
11.5 Deltanoid
11.5.1 Deltanoid Company Detail
11.5.2 Deltanoid Business Overview
11.5.3 Deltanoid Late Stage Chronic Kidney Disease Drugs Introduction
11.5.4 Deltanoid Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.5.5 Deltanoid Recent Development
11.6 Akebia Therapeutics
11.6.1 Akebia Therapeutics Company Detail
11.6.2 Akebia Therapeutics Business Overview
11.6.3 Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Introduction
11.6.4 Akebia Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.6.5 Akebia Therapeutics Recent Development
11.7 Kyowa Hakko Kirin
11.7.1 Kyowa Hakko Kirin Company Detail
11.7.2 Kyowa Hakko Kirin Business Overview
11.7.3 Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Introduction
11.7.4 Kyowa Hakko Kirin Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.7.5 Kyowa Hakko Kirin Recent Development
11.8 OPKO Health
11.8.1 OPKO Health Company Detail
11.8.2 OPKO Health Business Overview
11.8.3 OPKO Health Late Stage Chronic Kidney Disease Drugs Introduction
11.8.4 OPKO Health Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.8.5 OPKO Health Recent Development
11.9 Vifor Pharma
11.9.1 Vifor Pharma Company Detail
11.9.2 Vifor Pharma Business Overview
11.9.3 Vifor Pharma Late Stage Chronic Kidney Disease Drugs Introduction
11.9.4 Vifor Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.9.5 Vifor Pharma Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Late Stage Chronic Kidney Disease Drugs Introduction
11.10.4 Sanofi Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.10.5 Sanofi Recent Development
11.11 Shield Therapeutics
11.11.1 Shield Therapeutics Company Detail
11.11.2 Shield Therapeutics Business Overview
11.11.3 Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Introduction
11.11.4 Shield Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.11.5 Shield Therapeutics Recent Development
11.12 Shire
11.12.1 Shire Company Detail
11.12.2 Shire Business Overview
11.12.3 Shire Late Stage Chronic Kidney Disease Drugs Introduction
11.12.4 Shire Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.12.5 Shire Recent Development
11.13 Spectrum
11.13.1 Spectrum Company Detail
11.13.2 Spectrum Business Overview
11.13.3 Spectrum Late Stage Chronic Kidney Disease Drugs Introduction
11.13.4 Spectrum Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.13.5 Spectrum Recent Development
11.14 ZS Pharma
11.14.1 ZS Pharma Company Detail
11.14.2 ZS Pharma Business Overview
11.14.3 ZS Pharma Late Stage Chronic Kidney Disease Drugs Introduction
11.14.4 ZS Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
11.14.5 ZS Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables

List of Tables
Table 1. Global Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Calcimimetics
Table 3. Key Players of Vitamin D Sterols
Table 4. Key Players of Potassium Binders
Table 5. Key Players of Others
Table 6. Global Late Stage Chronic Kidney Disease Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Late Stage Chronic Kidney Disease Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Late Stage Chronic Kidney Disease Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Late Stage Chronic Kidney Disease Drugs Market Share by Region (2019-2024)
Table 10. Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Late Stage Chronic Kidney Disease Drugs Market Share by Region (2025-2030)
Table 12. Late Stage Chronic Kidney Disease Drugs Market Trends
Table 13. Late Stage Chronic Kidney Disease Drugs Market Drivers
Table 14. Late Stage Chronic Kidney Disease Drugs Market Challenges
Table 15. Late Stage Chronic Kidney Disease Drugs Market Restraints
Table 16. Global Late Stage Chronic Kidney Disease Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Late Stage Chronic Kidney Disease Drugs Market Share by Players (2019-2024)
Table 18. Global Top Late Stage Chronic Kidney Disease Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Late Stage Chronic Kidney Disease Drugs as of 2023)
Table 19. Ranking of Global Top Late Stage Chronic Kidney Disease Drugs Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Late Stage Chronic Kidney Disease Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Late Stage Chronic Kidney Disease Drugs Product Solution and Service
Table 23. Date of Enter into Late Stage Chronic Kidney Disease Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Late Stage Chronic Kidney Disease Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Type (2019-2024)
Table 27. Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Type (2025-2030)
Table 29. Global Late Stage Chronic Kidney Disease Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Application (2019-2024)
Table 31. Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Application (2025-2030)
Table 33. North America Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 48. AbbVie Company Detail
Table 49. AbbVie Business Overview
Table 50. AbbVie Late Stage Chronic Kidney Disease Drugs Product
Table 51. AbbVie Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 52. AbbVie Recent Development
Table 53. Amgen Company Detail
Table 54. Amgen Business Overview
Table 55. Amgen Late Stage Chronic Kidney Disease Drugs Product
Table 56. Amgen Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 57. Amgen Recent Development
Table 58. Ardelyx Company Detail
Table 59. Ardelyx Business Overview
Table 60. Ardelyx Late Stage Chronic Kidney Disease Drugs Product
Table 61. Ardelyx Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 62. Ardelyx Recent Development
Table 63. AstraZeneca Company Detail
Table 64. AstraZeneca Business Overview
Table 65. AstraZeneca Late Stage Chronic Kidney Disease Drugs Product
Table 66. AstraZeneca Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 67. AstraZeneca Recent Development
Table 68. Deltanoid Company Detail
Table 69. Deltanoid Business Overview
Table 70. Deltanoid Late Stage Chronic Kidney Disease Drugs Product
Table 71. Deltanoid Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 72. Deltanoid Recent Development
Table 73. Akebia Therapeutics Company Detail
Table 74. Akebia Therapeutics Business Overview
Table 75. Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Product
Table 76. Akebia Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 77. Akebia Therapeutics Recent Development
Table 78. Kyowa Hakko Kirin Company Detail
Table 79. Kyowa Hakko Kirin Business Overview
Table 80. Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Product
Table 81. Kyowa Hakko Kirin Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 82. Kyowa Hakko Kirin Recent Development
Table 83. OPKO Health Company Detail
Table 84. OPKO Health Business Overview
Table 85. OPKO Health Late Stage Chronic Kidney Disease Drugs Product
Table 86. OPKO Health Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 87. OPKO Health Recent Development
Table 88. Vifor Pharma Company Detail
Table 89. Vifor Pharma Business Overview
Table 90. Vifor Pharma Late Stage Chronic Kidney Disease Drugs Product
Table 91. Vifor Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 92. Vifor Pharma Recent Development
Table 93. Sanofi Company Detail
Table 94. Sanofi Business Overview
Table 95. Sanofi Late Stage Chronic Kidney Disease Drugs Product
Table 96. Sanofi Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 97. Sanofi Recent Development
Table 98. Shield Therapeutics Company Detail
Table 99. Shield Therapeutics Business Overview
Table 100. Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Product
Table 101. Shield Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 102. Shield Therapeutics Recent Development
Table 103. Shire Company Detail
Table 104. Shire Business Overview
Table 105. Shire Late Stage Chronic Kidney Disease Drugs Product
Table 106. Shire Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 107. Shire Recent Development
Table 108. Spectrum Company Detail
Table 109. Spectrum Business Overview
Table 110. Spectrum Late Stage Chronic Kidney Disease Drugs Product
Table 111. Spectrum Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 112. Spectrum Recent Development
Table 113. ZS Pharma Company Detail
Table 114. ZS Pharma Business Overview
Table 115. ZS Pharma Late Stage Chronic Kidney Disease Drugs Product
Table 116. ZS Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2019-2024) & (US$ Million)
Table 117. ZS Pharma Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Late Stage Chronic Kidney Disease Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Late Stage Chronic Kidney Disease Drugs Market Share by Type: 2023 VS 2030
Figure 3. Calcimimetics Features
Figure 4. Vitamin D Sterols Features
Figure 5. Potassium Binders Features
Figure 6. Others Features
Figure 7. Global Late Stage Chronic Kidney Disease Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Late Stage Chronic Kidney Disease Drugs Market Share by Application: 2023 VS 2030
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Online Pharnacies Case Studies
Figure 11. Retail Pharmacies Case Studies
Figure 12. Late Stage Chronic Kidney Disease Drugs Report Years Considered
Figure 13. Global Late Stage Chronic Kidney Disease Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Late Stage Chronic Kidney Disease Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Late Stage Chronic Kidney Disease Drugs Market Share by Region: 2023 VS 2030
Figure 16. Global Late Stage Chronic Kidney Disease Drugs Market Share by Players in 2023
Figure 17. Global Top Late Stage Chronic Kidney Disease Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Late Stage Chronic Kidney Disease Drugs as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Late Stage Chronic Kidney Disease Drugs Revenue in 2023
Figure 19. North America Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Late Stage Chronic Kidney Disease Drugs Market Share by Country (2019-2030)
Figure 21. United States Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Late Stage Chronic Kidney Disease Drugs Market Share by Country (2019-2030)
Figure 25. Germany Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Share by Region (2019-2030)
Figure 33. China Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Late Stage Chronic Kidney Disease Drugs Market Share by Country (2019-2030)
Figure 41. Mexico Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Share by Country (2019-2030)
Figure 45. Turkey Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. AbbVie Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 48. Amgen Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 49. Ardelyx Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 50. AstraZeneca Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 51. Deltanoid Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 52. Akebia Therapeutics Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 53. Kyowa Hakko Kirin Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 54. OPKO Health Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 55. Vifor Pharma Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 56. Sanofi Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 57. Shield Therapeutics Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 58. Shire Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 59. Spectrum Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 60. ZS Pharma Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock